March 11, 2020 / 3:49 PM / 23 days ago

BRIEF-Novavax And Serum Institute Of India To Develop And Commercialize Malaria Vaccine Candidate

March 11 (Reuters) - Novavax Inc:

* NOVAVAX AND SERUM INSTITUTE OF INDIA TO DEVELOP AND COMMERCIALIZE MALARIA VACCINE CANDIDATE

* NOVAVAX INC - AS PART OF ARRANGEMENT, CO GAINED RIGHTS TO SELL & DISTRIBUTE SII-MANUFACTURED VACCINE IN HIGH-INCOME COUNTRIES

* NOVAVAX INC - UNDER AGREEMENT, SII IS GRANTED RIGHTS TO USE MATRIX-M IN VACCINE IN REGIONS WHERE MALARIA IS ENDEMIC

* NOVAVAX - SII WILL PAY NOVAVAX ROYALTIES ON ITS MARKET SALES OF MALARIA VACCINE

* NOVAVAX - MATRIX-M WILL BE MANUFACTURED, SUPPLIED TO SII BY NOVAVAX AB, A WHOLLY-OWNED UNIT OF CO BASED IN UPPSALA, SWEDEN

* NOVAVAX - TOP-LINE DATA EXPECTED TO BE REPORTED IN Q2 OF 2020 FROM PHASE 2B MALARIA TRIAL Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below